Preclinical
Bavisant / BRAVEinMS shows a strong multi-model preclinical remyelination and neuroprotection signal
After screening more than 1,500 repurposable compounds, bavisant, a histamine H3-receptor antagonist, showed remyelination and neuroprotection across several models, including human oligodendroglial assays and a humanised chimeric mouse model.
Practical availability: Preclinical — not available as a clinical intervention
What this means clinically
This is one of the stronger new repurposing leads, but it remains preclinical. There is no registered trial in people with MS and no demonstrated clinical benefit.
Source quality: High for a preclinical finding • Science Translational Medicine
Peer-reviewed paperPubMed / Science Translational Medicine ↗